NCT06259162Recruiting
LAG3 Expression in Triple Negative Breast Cancer
The Evaluation the Relationship Between LAG-3 Expression / Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer
Source: ClinicalTrials.gov · Last updated 14 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- First submitted
- 6 Feb 2024
- Start date
- 18 Nov 2022
- Primary completion date
- 1 Jul 2025
- Lead sponsor
- Samsung Medical Center
- NCT number
- NCT06259162
What you commit to
- Study type: Interventional
- Planned participants: 128
- From 18 Nov 2022 to the primary completion date, 1 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- HER2-positive breast cancer
- Hormone receptor positive breast cancer
Who the study is looking for
- Planned neoadjuvant chemotherapy
- Triple negative breast cancer
Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ji-Yeon Kim Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.